Integration into International Sponsor Consortia for Trials of Innovative Products.

About

We offer our capacity and experience to integrate as a strategic partner into established European consortia that require executing preclinical and clinical trials. Our value lies in facilitating access to diverse study populations and a favorable regulatory environment, providing robust and high-quality data for the development and eventual registration of innovative products in Argentina and the region.

OUR APPROACH AND VALUE ADDED:

We have a network of institutions with broad capacity and demonstrated experience in conducting Phase I to IV preclinical and clinical studies, including observational trials, in various pathologies and neglected diseases. We have the necessary infrastructure and specialized teams to generate data that meets international standards: high-complexity university hospitals, national reference hospitals, a network of clinical laboratories with validated analytical capabilities, and alliances with global Contract Research Organizations (CROs).

Our specific added value is the capacity to recruit, retain, and follow diverse cohorts in real and diverse scenarios, from urban environments to dispersed rural populations. This guarantees not only data quality and strict local and international regulatory compliance but also offers a gateway to unique study populations representative of the region's health challenges. Among the interventions we have worked on are studies for new therapeutic regimens in oncology, large-scale pharmacovigilance programs, and long-term research on neglected infectious diseases. This capacity can be enhanced through integration with community digital transformation nodes for field data collection**.**

EXPECTED RESULT AND NEED FOR COOPERATION:

We aspire to the generation of solid scientific evidence, obtained in a unique geographical and population context, which forms the basis for therapeutic decisions, product registration, and the improvement of healthcare. The population, geographical, and climatic heterogeneity of Argentina, as well as its available human capital and infrastructure, provides an exceptionally favorable environment for this purpose. To materialize this collaboration, we seek to integrate into consortia that require:

• An executing partner with comprehensive capabilities to carry out specific segments of clinical development (from early phases to post-marketing) in an agile regulatory environment.

• Access to diverse patient populations and real-world health scenarios, including rural and peri-urban areas, for trials of innovative therapies, medical devices, or public health studies.

• A partner with experience in diseases of regional and global relevance, capable of guaranteeing data quality and traceability under GCP (Good Clinical Practice) standards and local and international regulations.

• Opportunities for co-submission to funding calls that require this profile of capabilities, particularly those aligned with Horizon Europe, Cluster 1 (Health) and biomedical research cooperation programs.

PROFILE OF THE EUROPEAN CONSORTIUM SOUGHT:

We seek to integrate into consortia led by European universities, research institutes, biotech, or pharmaceutical companies that have innovative products (drugs, advanced therapies, medical devices, or diagnostic solutions) in preclinical or early clinical development stages, and that require a strategic partner for the execution phase of trials. We especially value those consortia with a genuine interest in generating evidence that includes populations of the Global South, with a vision to scale the production and commercialization of their innovations, and that seek a reliable partner to expand the geographical reach and external validity of their research.

This integration represents a mutually beneficial cooperation opportunity: it accelerates the path to market for European innovations while strengthening local research capabilities and bringing advanced therapies to populations with specific needs, contributing to a more inclusive and representative clinical development.